Amedica Corporation Forecast and Stock Analysis
Technical AMDA stock analysis for February 21, 2019.
Amedica Corporation gained 1.96% in the last trading day, rising from $0.26 to $0.26 The price has been going up and down for this period, and there has been a 6.12% gain for the last 2 weeks. Volume fell in the last day by -336 665 shares, and in total, 250 025 shares bought and sold for approximately $65 006.50. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.
Close price at the end of the last trading day (Thursday, 21st Feb 2019) of the AMDA stock was $0.26. This is 1.96% more than the trading day before Wednesday, 20th Feb 2019.
During day the stock fluctuated 10.42% from a day low at $0.24 to a day high of $0.27.
30 day high of the AMDA stock price was $0.35 and low was $0.19.
90 day high was $0.35 and low was $0.16.
52 week high for the Amedica Corporation - $4.12 and low - $0.16.
Amedica Corporation lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 4.63% during the next 3 months and, with 90% probability hold a price between $0.18 and $0.32 at the end of this period.
Amedica Corporation holds a sales signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $0.28. On a fall, the stock will find some support from the long-term average at approximately $0.23. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sales signal. A buy signal was issued from a pivot bottom point on Wednesday February 20, 2019, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may not be. The very low volume increases the risk and reduces the other technical signals issued.
* Golden Star Signal* is when the short-term moving average, the long-term moving average, and price line meet in a special combination. This combination is very rare and often followed by long and strong gains for the stock in question.
Relative Strength Index (RSI)
RSI14 is 63 and the stock is currently not being overbought or oversold
Support & Resistance
On the downside, the stock finds support just below today's level from accumulated volume at $0.25 and $0.24.
There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Amedica Corporation finds support just below today's level at $0.25. If this is broken, then the next support from accumulated volume will be at $0.24 and $0.21.
This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.03 between high and low, or 10.42%. For the last week the stock has had a daily average volatility of 15.39%.
Our recommended stoploss: $0.24 (-6.17%) (This stock has very high daily movements and this gives very high risk. There is a buy signal from pivot bottom found 1 days ago.)
Very Low Low Medium High Very High
Evaluation: Buy Candidate
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term. We have upgraded our recommendation for this stock since last evaluation from a Hold/Accumulate to a Buy Candidate.